Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients

Chang Gyu Park, Jeong Cheon Ahn, Soon Jun Hong, Eung Ju Kim, Seung Jin Lee, Sung Mi Park, Hong Seog Seo, Dong Joo Oh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Increased aortic stiffness measured by pulse wave velocity (PWV) and left ventricular hypertrophy (LVH) are independent risk factors of cardiovascular events in hypertensive patients. We have conducted a prospective study to examine the effects of the angiotensin II receptor antagonist (irbesartan) on PWV and LVH in hypertensive patients. Methods: A total of 52 untreated hypertensive patients (age:53.3±8.0 yrs) were enrolled; they had no evidence of associated cardiovascular complications. Blood pressure, heart rate, aortic PWV and left ventricular mass index (LVMI) by 2-D echocardiography were measured at baseline and after irbesartan treatment (150 mg or 300 mg/day) at 12 weeks and 24 weeks. Results: Blood pressure was significantly decreased after 12 weeks and 24 weeks of treatment compared to baseline (SBP: 134.6±13.3 mmHg, 134.0±11.0 mmHg vs 163.7±13.8 mmHg p<0.001, DBP: 86.0±10 mmHg, 83.07 mmHg vs 102.4±9.6 mmHg p<0.001, respectively) without significant change in heart rate. LVMI decreased at 12 weeks and at 24 weeks after treatment compared to baseline (from 145.5±35.1 g/m2 at baseline to 137.5±35.4 g/m2 at 12 weeks, p=0.017 and 135.3±35.4 g/m2 at 24 weeks, p=0.008). Aortic PWV was decreased after irbesartan treatment at 12 weeks (from 9.6±2.8 m/sec to 8.7±3.1 m/sec at 12 weeks, p=0.064) and at 24 weeks (from 9.6±2.9 m/sec to 7.7±2.1 m/sec at 24 weeks, p=0.007). Conclusions: Long-term treatment with irbesartan may reduce arterial stiffness and regression of LVH in hypertensive patients. The pleiotropic effects of irbesartan, further decreasing PWV without change of BP between 12 and 24 weeks of treatment, may have favorable vascular effects on arterial stiffness and LVH.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalKorean Journal of Internal Medicine
Volume21
Issue number2
Publication statusPublished - 2006 Jun 1

Fingerprint

irbesartan
Vascular Stiffness
Pulse Wave Analysis
Left Ventricular Hypertrophy
Therapeutics
Heart Rate
Blood Pressure
Angiotensin Receptor Antagonists
Blood Vessels
Echocardiography
Prospective Studies

Keywords

  • Angiotensin
  • Aortic stiffness
  • Hypertension
  • Irbesartan
  • LVH
  • PWW

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients. / Park, Chang Gyu; Ahn, Jeong Cheon; Hong, Soon Jun; Kim, Eung Ju; Lee, Seung Jin; Park, Sung Mi; Seo, Hong Seog; Oh, Dong Joo.

In: Korean Journal of Internal Medicine, Vol. 21, No. 2, 01.06.2006, p. 103-108.

Research output: Contribution to journalArticle

@article{a05a76e30d9344928ff7ae6ff68663ca,
title = "Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients",
abstract = "Background: Increased aortic stiffness measured by pulse wave velocity (PWV) and left ventricular hypertrophy (LVH) are independent risk factors of cardiovascular events in hypertensive patients. We have conducted a prospective study to examine the effects of the angiotensin II receptor antagonist (irbesartan) on PWV and LVH in hypertensive patients. Methods: A total of 52 untreated hypertensive patients (age:53.3±8.0 yrs) were enrolled; they had no evidence of associated cardiovascular complications. Blood pressure, heart rate, aortic PWV and left ventricular mass index (LVMI) by 2-D echocardiography were measured at baseline and after irbesartan treatment (150 mg or 300 mg/day) at 12 weeks and 24 weeks. Results: Blood pressure was significantly decreased after 12 weeks and 24 weeks of treatment compared to baseline (SBP: 134.6±13.3 mmHg, 134.0±11.0 mmHg vs 163.7±13.8 mmHg p<0.001, DBP: 86.0±10 mmHg, 83.07 mmHg vs 102.4±9.6 mmHg p<0.001, respectively) without significant change in heart rate. LVMI decreased at 12 weeks and at 24 weeks after treatment compared to baseline (from 145.5±35.1 g/m2 at baseline to 137.5±35.4 g/m2 at 12 weeks, p=0.017 and 135.3±35.4 g/m2 at 24 weeks, p=0.008). Aortic PWV was decreased after irbesartan treatment at 12 weeks (from 9.6±2.8 m/sec to 8.7±3.1 m/sec at 12 weeks, p=0.064) and at 24 weeks (from 9.6±2.9 m/sec to 7.7±2.1 m/sec at 24 weeks, p=0.007). Conclusions: Long-term treatment with irbesartan may reduce arterial stiffness and regression of LVH in hypertensive patients. The pleiotropic effects of irbesartan, further decreasing PWV without change of BP between 12 and 24 weeks of treatment, may have favorable vascular effects on arterial stiffness and LVH.",
keywords = "Angiotensin, Aortic stiffness, Hypertension, Irbesartan, LVH, PWW",
author = "Park, {Chang Gyu} and Ahn, {Jeong Cheon} and Hong, {Soon Jun} and Kim, {Eung Ju} and Lee, {Seung Jin} and Park, {Sung Mi} and Seo, {Hong Seog} and Oh, {Dong Joo}",
year = "2006",
month = "6",
day = "1",
language = "English",
volume = "21",
pages = "103--108",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "2",

}

TY - JOUR

T1 - Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients

AU - Park, Chang Gyu

AU - Ahn, Jeong Cheon

AU - Hong, Soon Jun

AU - Kim, Eung Ju

AU - Lee, Seung Jin

AU - Park, Sung Mi

AU - Seo, Hong Seog

AU - Oh, Dong Joo

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Background: Increased aortic stiffness measured by pulse wave velocity (PWV) and left ventricular hypertrophy (LVH) are independent risk factors of cardiovascular events in hypertensive patients. We have conducted a prospective study to examine the effects of the angiotensin II receptor antagonist (irbesartan) on PWV and LVH in hypertensive patients. Methods: A total of 52 untreated hypertensive patients (age:53.3±8.0 yrs) were enrolled; they had no evidence of associated cardiovascular complications. Blood pressure, heart rate, aortic PWV and left ventricular mass index (LVMI) by 2-D echocardiography were measured at baseline and after irbesartan treatment (150 mg or 300 mg/day) at 12 weeks and 24 weeks. Results: Blood pressure was significantly decreased after 12 weeks and 24 weeks of treatment compared to baseline (SBP: 134.6±13.3 mmHg, 134.0±11.0 mmHg vs 163.7±13.8 mmHg p<0.001, DBP: 86.0±10 mmHg, 83.07 mmHg vs 102.4±9.6 mmHg p<0.001, respectively) without significant change in heart rate. LVMI decreased at 12 weeks and at 24 weeks after treatment compared to baseline (from 145.5±35.1 g/m2 at baseline to 137.5±35.4 g/m2 at 12 weeks, p=0.017 and 135.3±35.4 g/m2 at 24 weeks, p=0.008). Aortic PWV was decreased after irbesartan treatment at 12 weeks (from 9.6±2.8 m/sec to 8.7±3.1 m/sec at 12 weeks, p=0.064) and at 24 weeks (from 9.6±2.9 m/sec to 7.7±2.1 m/sec at 24 weeks, p=0.007). Conclusions: Long-term treatment with irbesartan may reduce arterial stiffness and regression of LVH in hypertensive patients. The pleiotropic effects of irbesartan, further decreasing PWV without change of BP between 12 and 24 weeks of treatment, may have favorable vascular effects on arterial stiffness and LVH.

AB - Background: Increased aortic stiffness measured by pulse wave velocity (PWV) and left ventricular hypertrophy (LVH) are independent risk factors of cardiovascular events in hypertensive patients. We have conducted a prospective study to examine the effects of the angiotensin II receptor antagonist (irbesartan) on PWV and LVH in hypertensive patients. Methods: A total of 52 untreated hypertensive patients (age:53.3±8.0 yrs) were enrolled; they had no evidence of associated cardiovascular complications. Blood pressure, heart rate, aortic PWV and left ventricular mass index (LVMI) by 2-D echocardiography were measured at baseline and after irbesartan treatment (150 mg or 300 mg/day) at 12 weeks and 24 weeks. Results: Blood pressure was significantly decreased after 12 weeks and 24 weeks of treatment compared to baseline (SBP: 134.6±13.3 mmHg, 134.0±11.0 mmHg vs 163.7±13.8 mmHg p<0.001, DBP: 86.0±10 mmHg, 83.07 mmHg vs 102.4±9.6 mmHg p<0.001, respectively) without significant change in heart rate. LVMI decreased at 12 weeks and at 24 weeks after treatment compared to baseline (from 145.5±35.1 g/m2 at baseline to 137.5±35.4 g/m2 at 12 weeks, p=0.017 and 135.3±35.4 g/m2 at 24 weeks, p=0.008). Aortic PWV was decreased after irbesartan treatment at 12 weeks (from 9.6±2.8 m/sec to 8.7±3.1 m/sec at 12 weeks, p=0.064) and at 24 weeks (from 9.6±2.9 m/sec to 7.7±2.1 m/sec at 24 weeks, p=0.007). Conclusions: Long-term treatment with irbesartan may reduce arterial stiffness and regression of LVH in hypertensive patients. The pleiotropic effects of irbesartan, further decreasing PWV without change of BP between 12 and 24 weeks of treatment, may have favorable vascular effects on arterial stiffness and LVH.

KW - Angiotensin

KW - Aortic stiffness

KW - Hypertension

KW - Irbesartan

KW - LVH

KW - PWW

UR - http://www.scopus.com/inward/record.url?scp=33748417288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748417288&partnerID=8YFLogxK

M3 - Article

C2 - 16913439

AN - SCOPUS:33748417288

VL - 21

SP - 103

EP - 108

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 2

ER -